Akeso (09926) rose more than 5%, as of publishing, up 5.19% at HKD 40.55, with a turnover of HKD 0.168 billion.
It's reported on the WiseNews app that Akeso (09926) rose more than 5%, as of publishing, up 5.19% at HKD 40.55, with a turnover of HKD 0.168 billion.
On the news front, Akeso announced today that in the mid-term analysis of the AK104-303 Phase III clinical trial for first-line treatment of persistent, recurrent, or metastatic cervical cancer with PD-1/CTLA-4 bispecific antibody Carduner and platinum-containing chemotherapy+/- bevacizumab and placebo-containing platinum-containing chemotherapy+/- bevacizumab, a major research endpoint for overall survival (OS) was achieved. In November last year, the study had already achieved a major research endpoint for progression-free survival (PFS) in the mid-term analysis.
Guolian Securities pointed out that Akeso is the first domestic enterprise to commercialize bispecific antibodies, with a layout in tumor bispecific antibodies, immunomodulators, and lipid-lowering drugs. The company currently has over 100 million varieties, including Carduner and Pai An Pu Li, two antibody drugs, with sales revenue of over CNY 1 billion in the first full year for Carduner, a drug for cervical cancer; the upfront payment for the in-development lung cancer drug Ivoxi has reached USD 0.5 billion, which is expected to be launched domestically in 2024 and subsequently internationally marketed; two immunomodulators and lipid-lowering drugs are expected to receive marketing approval in non-tumor areas in 2024.